Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies
Byrne J, Healy C, Föcking M, Heurich M, Susai S, Mongan D, Wynne K, Kodosaki E, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, Jeffries C, Perkins D, Cotter D. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain Behavior And Immunity 2024, 119: 188-196. PMID: 38555993, DOI: 10.1016/j.bbi.2024.03.049.Peer-Reviewed Original ResearchNegative symptomsDepressive symptomsScale of Psychosis-risk SymptomsMeasures of negative symptomsNorth American Prodrome Longitudinal Study 2Psychosis-risk symptomsClinical high riskPrognostic factorsLongitudinal Study 2Positive symptomsNAPLS 2Psychotic disordersAntipsychotic usePsychotic experiencesCannabis useSuicidal ideationAntidepressant useStudy 2Regulation groupQuality of life of individualsGroup factorsCurrent treatment optionsDemographic prognostic factorsPsychosisCoagulation proteins